In this issue:
- Triplets, transplant and maintenance until myeloma progression
- p53 isoform expression predicts MM survival
- MRD and imaging-guided consolidation in MM
- Frontline bortezomib + high-dose melphalan conditioning in MM
- Survival after autologous SCT in newly diagnosed MM with high-risk cytogenetics
- MM and other cancer risk in first- and second-degree relatives of MM patients
- Long-term follow-up after anti-BCMA + anti-CD19 CAR T-cells in MM
- Adding elotuzumab to lenalidomide-dexamethasone in new, transplant-ineligible MM
- Allogeneic SCT plus novel drugs in MM
- Adding isatuximab to carfilzomib-dexamethasone in relapsed MM with renal impairment
Please login below to download this issue (PDF)